AKT1 and idiopathic pulmonary fibrosis: Although they are yet to be repurposed for clinical studies in IPF, Akt degraders exhibit a longer half-life and a more prolonged pharmacological effect compared to their constituent Akt inhibitors alone (81), which could provide added benefits in terms of dose reduction.